Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate
- 4 Downloads
Combined chronic treatment of Ehrlich solid carcinoma (EC) with an NOS inhibitor 1-isobutanoyl-2-isopropylisothiourea hydrobromide (T1023) and a PDK1 inhibitor dichloroacetate was accompanied by statistically significant synergetic antitumor effects manifested in a significant and stable suppression of neoplasm growth (by 55-65%). Separate treatment with T1023 and dichloroacetate induced moderate short-term inhibition of tumor growth (by 30-35%) followed by weakening of tumor sensitivity to these substances. These results attest to synergetic antitumor effects NOS inhibitor T1023 and PDK1 inhibitor dichloroacetate producing antiangiogenic and hypoxia-targeted cytotoxic effects, during their combined administration, which allows overcoming the adaptive potential of the tumors.
Key WordsNOS inhibitors PDK1 inhibitor Ehrlich carcinoma hypoxic resistance
Unable to display preview. Download preview PDF.
- 2.Koblyakov VA. Hypoxic state and glycolysis as a possible anticancer therapeutic target. Uspekhi Mol. Onkol. 2014;1(2):44-49. Russian.Google Scholar
- 3.Osinskii S, Vaupel P. Microphysiology of Tumors. Kiev, 2009. Russian.Google Scholar
- 4.Filimononva MV, Shevchenko LI, Yuzhakov VV, Marchuk VM, Lushnikova GA. Experimental and theoretical designing of new-generation anti-shock and antitumor agents based on NO-synthase inhibitors. Proceedings of the Regional Competition of Basic Research Projects. Kaluga, 2014. Vol. 19. P. 151-155. Russian.Google Scholar
- 5.Filimonova MV, Yuzhakov VV, Shevchenko LI, Bandurko LN, Sevankaeva LE, Makarchuk VM, Chesnakova EA, Shevchuk AS, Tsyganova MG, Fomina NK, Ingel IE, Surinova VI. Experimental study of antitumor activity of new nitric oxide synthase inhibitor T1023. Mol. Med. 2015;(1):61-64. Russian.Google Scholar